UCB SA (UCBJF)
USD 195.88
(0.0%)
USD 195.88
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.94 Billion EUR | -2.48% |
| 2022 | 3.14 Billion EUR | 4.11% |
| 2021 | 3.01 Billion EUR | 4.61% |
| 2020 | 2.88 Billion EUR | 12.13% |
| 2019 | 2.57 Billion EUR | 13.25% |
| 2018 | 2.27 Billion EUR | 3.56% |
| 2017 | 2.19 Billion EUR | 9.16% |
| 2016 | 2 Billion EUR | 0.35% |
| 2015 | 2 Billion EUR | 6.38% |
| 2014 | 1.88 Billion EUR | 4.04% |
| 2013 | 1.8 Billion EUR | -6.37% |
| 2012 | 1.93 Billion EUR | 5.98% |
| 2011 | 1.82 Billion EUR | 7.36% |
| 2010 | 1.69 Billion EUR | 60.95% |
| 2009 | 1.05 Billion EUR | -44.76% |
| 2008 | 1.91 Billion EUR | -8.0% |
| 2007 | 2.07 Billion EUR | 49.89% |
| 2006 | 1.38 Billion EUR | 1.84% |
| 2005 | 1.36 Billion EUR | -35.92% |
| 2004 | 2.12 Billion EUR | 11.05% |
| 2003 | 1.91 Billion EUR | 721.76% |
| 2002 | -307.36 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 815 Million EUR | -44.86% |
| 2024 Q2 | 808.5 Million EUR | -0.8% |
| 2023 Q3 | 826 Million EUR | -31.68% |
| 2023 Q1 | 634 Million EUR | -59.07% |
| 2023 FY | 3.06 Billion EUR | -2.48% |
| 2023 Q4 | 1.47 Billion EUR | 78.93% |
| 2023 Q2 | 1.2 Billion EUR | 90.69% |
| 2022 Q4 | 1.54 Billion EUR | 0.0% |
| 2022 Q2 | 1.44 Billion EUR | 90.73% |
| 2022 Q1 | 755.5 Million EUR | -51.16% |
| 2022 FY | 3.14 Billion EUR | 4.11% |
| 2021 FY | 3.01 Billion EUR | 4.61% |
| 2021 Q4 | 1.54 Billion EUR | 87.29% |
| 2021 Q3 | 826 Million EUR | -37.23% |
| 2021 Q2 | 1.31 Billion EUR | 84.57% |
| 2021 Q1 | 713 Million EUR | -52.31% |
| 2020 Q2 | 1.23 Billion EUR | 75.82% |
| 2020 Q4 | 1.49 Billion EUR | 81.87% |
| 2020 Q1 | 703 Million EUR | -46.38% |
| 2020 FY | 2.88 Billion EUR | 12.13% |
| 2020 Q3 | 822 Million EUR | -33.5% |
| 2019 Q4 | 1.31 Billion EUR | 0.0% |
| 2019 FY | 2.57 Billion EUR | 13.25% |
| 2019 Q1 | 564 Million EUR | 0.0% |
| 2019 Q2 | 1.09 Billion EUR | 93.44% |
| 2018 Q2 | 510.5 Million EUR | 0.0% |
| 2018 FY | 2.27 Billion EUR | 3.56% |
| 2018 Q1 | 510.5 Million EUR | -18.52% |
| 2017 FY | 2.19 Billion EUR | 9.16% |
| 2017 Q2 | 495.5 Million EUR | 0.0% |
| 2017 Q1 | 495.5 Million EUR | -14.27% |
| 2017 Q4 | 626.5 Million EUR | 0.0% |
| 2017 Q3 | 626.5 Million EUR | 26.44% |
| 2016 Q1 | 485.5 Million EUR | -22.94% |
| 2016 FY | 2 Billion EUR | 0.35% |
| 2016 Q3 | 578 Million EUR | 19.05% |
| 2016 Q4 | 578 Million EUR | 0.0% |
| 2016 Q2 | 485.5 Million EUR | 0.0% |
| 2015 Q4 | 630 Million EUR | 0.0% |
| 2015 Q1 | 476.5 Million EUR | -15.96% |
| 2015 Q2 | 476.5 Million EUR | 0.0% |
| 2015 Q3 | 630 Million EUR | 32.21% |
| 2015 FY | 2 Billion EUR | 6.38% |
| 2014 Q1 | 475.5 Million EUR | 0.42% |
| 2014 Q3 | 567 Million EUR | 19.24% |
| 2014 Q2 | 475.5 Million EUR | 0.0% |
| 2014 Q4 | 567 Million EUR | 0.0% |
| 2014 FY | 1.88 Billion EUR | 4.04% |
| 2013 Q3 | 473.5 Million EUR | -3.37% |
| 2013 Q1 | 490 Million EUR | 0.0% |
| 2013 FY | 1.8 Billion EUR | -6.37% |
| 2013 Q4 | 473.5 Million EUR | 0.0% |
| 2013 Q2 | 490 Million EUR | 0.0% |
| 2012 FY | 1.93 Billion EUR | 5.98% |
| 2011 FY | 1.82 Billion EUR | 7.36% |
| 2010 FY | 1.69 Billion EUR | 60.95% |
| 2009 FY | 1.05 Billion EUR | -44.76% |
| 2008 FY | 1.91 Billion EUR | -8.0% |
| 2007 FY | 2.07 Billion EUR | 49.89% |
| 2006 FY | 1.38 Billion EUR | 1.84% |
| 2005 FY | 1.36 Billion EUR | -35.92% |
| 2004 FY | 2.12 Billion EUR | 11.05% |
| 2003 FY | 1.91 Billion EUR | 721.76% |
| 2002 FY | -307.36 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -3288.834% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -59701.79% |
| SQZ Biotechnologies Company | 85.61 Million USD | -3334.985% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -9851.612% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -7794.1% |
| Mesoblast Limited | 5.9 Million USD | -49730.566% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -195718.76% |
| Genus plc | 147.7 Million USD | -1891.198% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -33399.506% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -219124.849% |
| Marizyme, Inc. | 19.23 Million USD | -15185.996% |
| ContraFect Corporation | 56.88 Million USD | -5069.716% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -35168.018% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -66609.431% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -198783.924% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -100749.211% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -105298.7% |
| MultiCell Technologies, Inc. | 567.42 USD | -518310851.324% |
| Accustem Sciences Inc. | 3.74 Million USD | -78401.63% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -3321.956% |
| EV Biologics, Inc. | 531.96 Thousand USD | -552759.039% |
| Q BioMed Inc. | 3.43 Million USD | -85478.072% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -11799.656% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -754842.68% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -111830.557% |
| Biomind Labs Inc. | 994.18 Thousand USD | -295721.087% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | -1204.265% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -43677.812% |
| Skye Bioscience, Inc. | 13.54 Million USD | -21608.722% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -143454.099% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 11764100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -58229.519% |
| IMV Inc. | 37.7 Million USD | -7699.155% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -18269.497% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -160164.183% |
| GB Sciences, Inc. | 1.42 Million USD | -206938.463% |
| Alpha Cognition Inc. | 9.7 Million USD | -30202.091% |
| HST Global, Inc. | 140.9 Thousand USD | -2087092.262% |
| CSL Limited | 3.44 Billion USD | 14.729% |
| Halberd Corporation | 74.84 Thousand USD | -3929511.715% |
| Enzolytics Inc. | 2.17 Million USD | -134838.773% |
| Resverlogix Corp. | 12.71 Million USD | -23035.62% |
| Affymax, Inc. | 39.38 Million USD | -7367.12% |
| SYBLEU INC | 160.87 Thousand USD | -1828016.065% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -80459.738% |
| argenx SE | 1.53 Billion USD | -91.78% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -5020.125% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -281604.981% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -186115.259% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -86273.514% |
| AVAX Technologies, Inc. | 7.31 Million USD | -40131.105% |
| Zenith Capital Corp. | 8.94 Million USD | -32786.056% |
| Genscript Biotech Corporation | 825.34 Million USD | -256.336% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -16881824.115% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -119680.867% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1714678.816% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -2860.833% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -167032.85% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -149035.36% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -157647.657% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -26963.587% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -153004.837% |
| BioStem Technologies, Inc. | 22.97 Million USD | -12700.981% |
| ONE Bio Corp. | 6.44 Million USD | -45540.119% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1620419.602% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -220128.525% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -261343.138% |
| Agentix Corp. | 1.37 Million USD | -214296.729% |
| LadRx Corporation | 3.81 Million USD | -77055.332% |
| Cell Source, Inc. | 4.32 Million USD | -67894.56% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -707757.678% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -318358.923% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -318358.923% |
| NovAccess Global Inc. | 2.46 Million USD | -119125.17% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -122190.258% |
| Itoco Inc. | 919.14 Thousand USD | -319871.974% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -69289.163% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -262723.95% |
| Kadimastem Ltd | 2.41 Million USD | -121927.524% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1123594.245% |
| CytoDyn Inc. | 18.05 Million USD | -16186.41% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -11684909.337% |
| Mobile Lads Corp. | 554.54 Thousand USD | -530243.741% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1336244.387% |
| Qrons Inc. | 643.67 Thousand USD | -456806.181% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -207043.018% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -131790.564% |
| Rebus Holdings, Inc. | 664 Thousand USD | -442821.687% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -161820.807% |
| International Stem Cell Corporation | 5.27 Million USD | -55695.864% |
| Bioxytran, Inc. | 3.82 Million USD | -76886.566% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -5586693.815% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -14456961.397% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -8009.524% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -181667.614% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -399581.994% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -94435.519% |
| Neutra Corp. | 243.82 Thousand USD | -1206112.754% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -16747.11% |
| PureTech Health plc | 144.59 Million USD | -1933.929% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -14253.422% |
| IXICO plc | 4.7 Million USD | -62381.411% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -33331.852% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -2397.707% |
| CSL Limited | 3.89 Billion USD | 24.454% |
| Cellectis S.A. | 97.32 Million USD | -2921.989% |